Johnson & Johnson (NYSE:JNJ) has lost a court battle over its drug-coated stent patents after a New Jersey federal judge ruled that stents marketed by Boston Scientific (NYSE:BSX) Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) had not infringed stent patents held by the New Brunswick, New Jersey company.
Despite the ruling, a Johnson & Johnson spokeswoman said in an email that the company would appeal the decision.
Johnson & Johnson ended its drug-coated stent business last year and exited a lucrative $4 billion market amidst setbacks in its business that included manufacturing problems, unfavorable patent decisions and greater competition.
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
In 2010, Boston Scientific agreed to pay J&J $1.73 billion to end other patent lawsuits between the companies over stent technology.